Pancreatic Cancer Research

Clinical trialPhase 1Terminated

A Study of SGN-STNV in Advanced Solid Tumors

A Phase 1 Study of SGN-STNV in Advanced Solid Tumors

Outcome
Stopped earlyStudy closed due to portfolio prioritization (Business decision)
Phase
Phase 1
Status
Terminated
Study type
Interventional
Start
18 January 2021
Ended
1 March 2024
Enrollment
111 participants
Sites
18
Primary outcomes
Incidence of adverse events (AEs); Incidence of laboratory abnormalities; Incidence of dose limiting toxicities
Sponsor type
Industry
Results posted
No
Last update
7 February 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.

Detailed description public domain (ClinicalTrials.gov)

The study will include dose escalation (Part A) and dose expansion (Part B), with multiple disease-specific cohorts and a biology cohort in dose expansion. The biology cohort will require additional biopsies. At the completion of dose escalation, up to 5 disease specific expansion cohorts and 1 biology expansion cohort may be activated by the sponsor in consultation with the Safety Monitoring Committee (SMC). Expansion cohorts in Part B will enroll subjects with selected tumors that are eligible for enrollment in Part A. The dose(s) to be examined in Part B will be at or below the maximum tolerated dose and/or the recommended dose determined in Part A. The recommended dose and/or schedule may differ between cohorts.